NewAmsterdam Pharma (NAMS) Competitors $21.54 -0.48 (-2.18%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$21.52 -0.02 (-0.09%) As of 07/11/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. BBIO, BPMC, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVLShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Its Competitors BridgeBio Pharma Blueprint Medicines Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Nuvalent BridgeBio Pharma (NASDAQ:BBIO) and NewAmsterdam Pharma (NASDAQ:NAMS) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings. Do analysts prefer BBIO or NAMS? BridgeBio Pharma currently has a consensus price target of $60.21, indicating a potential upside of 29.58%. NewAmsterdam Pharma has a consensus price target of $42.89, indicating a potential upside of 99.11%. Given NewAmsterdam Pharma's higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BBIO or NAMS more profitable? NewAmsterdam Pharma has a net margin of -397.45% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-524.25% N/A -94.43% NewAmsterdam Pharma -397.45%-37.34%-33.45% Which has stronger valuation and earnings, BBIO or NAMS? NewAmsterdam Pharma has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$221.90M39.76-$535.76M-$3.53-13.16NewAmsterdam Pharma$45.56M53.08-$241.60M-$1.88-11.46 Which has more volatility and risk, BBIO or NAMS? BridgeBio Pharma has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Does the media favor BBIO or NAMS? In the previous week, BridgeBio Pharma had 12 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 15 mentions for BridgeBio Pharma and 3 mentions for NewAmsterdam Pharma. BridgeBio Pharma's average media sentiment score of 0.64 beat NewAmsterdam Pharma's score of 0.47 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in BBIO or NAMS? 99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryNewAmsterdam Pharma beats BridgeBio Pharma on 8 of the 15 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.42B$2.42B$5.55B$9.11BDividend YieldN/A1.81%5.07%4.01%P/E Ratio-11.469.4228.2120.26Price / Sales53.08727.21431.9599.73Price / CashN/A164.4637.1257.67Price / Book2.634.608.045.49Net Income-$241.60M$31.26M$3.19B$250.45M7 Day Performance8.54%4.80%3.63%4.79%1 Month Performance2.43%5.42%4.06%7.68%1 Year Performance8.40%-4.36%30.02%16.44% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma2.706 of 5 stars$21.54-2.2%$42.89+99.1%+2.6%$2.42B$45.56M-11.464Positive NewsBBIOBridgeBio Pharma4.6022 of 5 stars$43.50-1.1%$58.85+35.3%+72.8%$8.35B$221.90M-12.32400Analyst UpgradeBPMCBlueprint Medicines1.2227 of 5 stars$128.40+0.0%$128.25-0.1%+9.8%$8.29B$508.82M-51.98640Positive NewsInsider TradeVRNAVerona Pharma PLC American Depositary Share2.3772 of 5 stars$91.20-0.4%$107.36+17.7%+394.0%$7.79B$42.28M-45.6030Trending NewsAnalyst ForecastROIVRoivant Sciences2.8383 of 5 stars$10.74-2.3%$17.50+62.9%+1.1%$7.47B$29.05M-42.96860Analyst UpgradeELANElanco Animal Health1.5121 of 5 stars$14.48-1.1%$15.33+5.9%+9.0%$7.27B$4.44B19.579,000News CoverageRVMDRevolution Medicines4.5725 of 5 stars$36.67-3.2%$68.00+85.4%-12.3%$7.05B$11.58M-9.17250LEGNLegend Biotech3.3947 of 5 stars$35.87+0.6%$72.60+102.4%-19.7%$6.55B$627.24M-60.802,609Analyst ForecastGRFSGrifols3.5701 of 5 stars$8.87-2.3%$10.30+16.1%+10.1%$6.24B$7.81B7.5823,822News CoverageTGTXTG Therapeutics3.7893 of 5 stars$35.98-2.0%$40.80+13.4%+73.4%$5.83B$329M149.92290News CoverageAnalyst UpgradeNUVLNuvalent3.372 of 5 stars$77.93-3.2%$119.60+53.5%+3.8%$5.78BN/A-17.7540Insider Trade Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Verona Pharma PLC American Depositary Share Alternatives Roivant Sciences Alternatives Elanco Animal Health Alternatives Revolution Medicines Alternatives Legend Biotech Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Company N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMS Stock Alerts